<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245670</url>
  </required_header>
  <id_info>
    <org_study_id>5STAR-PC</org_study_id>
    <nct_id>NCT04245670</nct_id>
  </id_info>
  <brief_title>5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:</brief_title>
  <acronym>5STAR-PC</acronym>
  <official_title>5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:A Phase II Study (5STAR-PC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostate Cure Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously
      treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and
      up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.

      5-fraction SABR is a feasible, well-tolerated, effective and cost effective treatment for
      high-intermediate and high risk prostate cancer with/without an image-guided intraprostatic
      boost.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>Baseline to 3 months post completion of treatment</time_frame>
    <description>To document the acute urinary toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0) criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>Baseline to 3 months post completion of treatment</time_frame>
    <description>To document the acute bowel toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life outcome</measure>
    <time_frame>Baseline to end of 5 year follow up</time_frame>
    <description>Measuring quality of life using Expanded Prostate Index Composite (EPIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical disease-free survival</measure>
    <time_frame>Baseline to end of 5 year follow up</time_frame>
    <description>Biochemical disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcome</measure>
    <time_frame>Baseline to end of 5 year follow up</time_frame>
    <description>Health utilities using the EQ-5D Quality of Life Questionnaire tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcome</measure>
    <time_frame>Baseline to end of 5 year follow up</time_frame>
    <description>Health utilities using PORPUS-U Quality of Life Questionnaire tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic analysis</measure>
    <time_frame>Baseline to end of 5 year follow up</time_frame>
    <description>Cost effectiveness of treatment.Quality of life and cost estimates will be captured for each patient from time of the initiation of treatment until death. The effectiveness endpoints will be biochemical disease free survival and quality-adjusted life years (QALYs). QALY will be calculated by survival (in years) multiplied by a utility weight associated with a certain condition.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5</intervention_name>
    <description>Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.</description>
    <arm_group_label>Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histologically confirmed prostate adenocarcinoma (centrally reviewed)

          -  High-intermediate risk defined as two or more of: T2c, Gleason 7 OR PSA 10-20ng/ml,

          -  High-risk prostate cancer, defined as at least one of: T3, Gleason 8-10, OR PSA &gt; 20
             ng/mL

          -  Willing to give informed consent to participate in this clinical trial

          -  Able and willing to complete EPIC, PORPUS and EQ-5D questionnaires

        Exclusion Criteria

          -  Prior pelvic radiotherapy

          -  Contraindication to radical prostate radiotherapy e.g. connective tissue disease or
             inflammatory bowel disease

          -  Anticoagulation medication (if unsafe to discontinue for fiducial insertion)

          -  Diagnosis of bleeding diathesis

          -  Poor baseline urinary function defined as International Prostate Symptom Score (IPSS)
             &gt;20

          -  Evidence of castrate resistance (defined as PSA &lt; 3 ng/ml while testosterone is &lt;
             0.7nmol/l. Patients could have been on combined androgen blockade but are excluded if
             this was started due to PSA progression.

          -  Definitive extrapelvic nodal or distant metastatic disease on staging investigations.

          -  Hip prosthesis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male patients with Prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Loblaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Loblaw, MD</last_name>
    <phone>416-480-5000</phone>
    <phone_ext>4806</phone_ext>
    <email>andrew.loblaw@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea DeAbreu</last_name>
    <phone>416-480-5000</phone>
    <phone_ext>1058</phone_ext>
    <email>andrea.deabreu@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontairo</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea DeAbreu</last_name>
      <phone>416-480-5000</phone>
      <phone_ext>1058</phone_ext>
      <email>andrea.deabreu@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Loblaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard Morton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Cheung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Chu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danny Vesprini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melanie Davidson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rene Korol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ananth Ravi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanley Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Tseng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Analysis of acute toxicity will be performed approximately 6 months after the last patient has been accrued, in August 2020. The final analysis will be performed when all patients have completed 5 years of follow-up, in early 2025.</ipd_time_frame>
    <ipd_access_criteria>The primary endpoint analysis will be shared thru publications</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

